Impact of mast cell chymase on renal disease progression

Current Hypertension Reviews

Volumn 8, Issue 1, 2012, Pages 15-23

  Wasse, Haimanot ^a   Naqvi, Nawazish ^a   Husain, Ahsan ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin II; Chymase; Kidney disease; Mast cells; Transforming growth factor

Indexed keywords

4[1 (4 METHYL BENZO[B]THIOPHEN 3 YLMETHYL) 1H BENZIMIDAZOL 2 YLSULFANYL]BUTYRIC ACID; ANGIOTENSIN II; CHYMASE; CHYMASE INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; OLMESARTAN; RAMIPRIL; TEIE 00548; TEIE 00806; UNCLASSIFIED DRUG;

ARTICLE; CELL DENSITY; CELLULAR DISTRIBUTION; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DISEASE COURSE; DISEASE SEVERITY; EXTRACELLULAR MATRIX; GLOMERULONEPHRITIS; GLOMERULUS BASEMENT MEMBRANE; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY ISCHEMIA; MAST CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; TUBULAR DYSFUNCTION;

EID: 84870162359     PISSN: 15734021     EISSN: 18756506     Source Type: Journal    
DOI: 10.2174/157340212800505007     Document Type: Article

References (86)

1. Wolters PJ, Pham CT, Muilenburg DJ, Ley TJ, Caughey GH. Dipeptidyl peptidase I is essential for activation of mast cell chymases, but not tryptases, in mice. J Biol Chem 2001; 276(21): 18551-18556.
2. Metcalfe DD, Baram D, Mekori YA. Mast cells. Physiol Rev 1997; 77(4): 1033-1079.
3. Yurt R, Austen KF. Preparative purification of the rat mast cell chymase: characterization and interaction with granule components. J Exp Med 1977; 146(5): 1405-1419.
4. Lindstedt L, Lee M, Kovanen PT. Chymase bound to heparin is resistant to its natural inhibitors and capable of proteolyzing high density lipoproteins in aortic intimal fluid. Atherosclerosis 2001; 155(1): 87-97.
5. Takai S, Shiota N, Jin D, Miyazaki M. Functional role of chymase in angiotensin II formation in human vascular tissue. J Cardiovasc Pharmacol 1998; 32(5): 826-833.
6. Wei CC, Hase N, Inoue Y, et al. Mast cell chymase limits the cardiac efficacy of Ang I-converting enzyme inhibitor therapy in rodents. J Clin Invest 2010; 120(4): 1229-1239.
7. Li M, Liu K, Michalicek J, et al. Involvement of chymase-mediated angiotensin II generation in blood pressure regulation. J Clin Invest 2004; 114(1): 112-120.
8. Lindstedt KA, Wang Y, Shiota N, et al. Activation of paracrine TGF-beta1 signaling upon stimulation and degranulation of rat serosal mast cells: a novel function for chymase. FASEB J 2001; 15(8): 1377-1388.
9. Maurer M, Wedemeyer J, Metz M, et al. Mast cells promote homeostasis by limiting endothelin-1-induced toxicity. Nature 2004; 432(7016): 512-516.
10. Chandrasekharan UM, Sanker S, Glynias MJ, Karnik SS, Husain A. Angiotensin II-forming activity in a reconstructed ancestral chymase. Science 1996; 271(5248): 502-505.
11. Sanker S, Chandrasekharan UM, Wilk D, Glynias MJ, Karnik SS, Husain A. Distinct multisite synergistic interactions determine substrate specificities of human chymase and rat chymase-1 for angiotensin II formation and degradation. J Biol Chem 1997; 272(5): 2963-2968.
12. Caughey GH, Raymond WW, Wolters PJ. Angiotensin II generation by mast cell alpha-and beta-chymases. Biochim Biophys Acta 2000; 1480(1-2): 245-257.
13. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990; 265(36): 22348-22357.
14. Urata H, Boehm KD, Philip A, et al. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest 1993; 91(4): 1269-1281.
15. Pavone-Macaluso M. Tissue mast cells in renal diseases. Acta Pathol Microbiol Scand 1960; 50: 337-346.
16. Lajoie G, Nadasdy T, Laszik Z, Blick KE, Silva FG. Mast cells in acute cellular rejection of human renal allografts. Mod Pathol 1996; 9(12): 1118-1125.
17. Ehara T, Shigematsu H. Mast cells in the kidney. Nephrology (Carlton). Jun 2003; 8(3): 130-138.
18. Hiromura K, Kurosawa M, Yano S, Naruse T. Tubulointerstitial mast cell infiltration in glomerulonephritis. Am J Kidney Dis 1998; 32(4): 593-599.
19. Toth T, Toth-Jakatics R, Jimi S, Ihara M, Urata H, Takebayashi S. Mast cells in rapidly progressive glomerulonephritis. J Am Soc Nephrol 1999; 10(7): 1498-1505.
20. Pardo J, Diaz L, Errasti P, et al. Mast cells in chronic rejection of human renal allografts. Virchows Arch Aug 2000; 437(2): 167-172.
21. Roberts IS, Brenchley PE. Mast cells: the forgotten cells of renal fibrosis. J Clin Pathol 2000; 53(11): 858-862.
22. Kitamura Y. Heterogeneity of mast cells and phenotypic change between subpopulations. Annu Rev Immunol 1989; 7: 59-76.
23. Rodewald HR, Dessing M, Dvorak AM, Galli SJ. Identification of a committed precursor for the mast cell lineage. Science 1996; 271(5250): 818-822.
24. Holdsworth SR, Summers SA. Role of mast cells in progressive renal diseases. J Am Soc Nephrol 2008; 19(12): 2254-2261.
25. Dawicki W, Marshall JS. New and emerging roles for mast cells in host defence. Curr Opin Immunol 2007; 19(1): 31-38.
26. Welker P, Kramer S, Groneberg DA, et al. Increased mast cell number in human hypertensive nephropathy. Am J Physiol Renal Physiol 2008; 295(4): F1103-1109.
27. Kovacs EJ. Fibrogenic cytokines: the role of immune mediators in the development of scar tissue. Immunol Today 1991; 12(1): 17-23.
28. Thompson HL, Burbelo PD, Metcalfe DD. Regulation of adhesion of mouse bone marrow-derived mast cells to laminin. J Immunol 1990; 145(10): 3425-3431.
29. Irani AM, Bradford TR, Kepley CL, Schechter NM, Schwartz LB. Detection of MCT and MCTC types of human mast cells by immunohistochemistry using new monoclonal anti-tryptase and anti-chymase antibodies. J Histochem Cytochem 1989; 37(10): 1509-1515.
30. Colvin RB, Dvorak AM, Dvorak HF. Mast cells in the cortical tubular epithelium and interstitium in human renal disease. Hum Pathol 1974; 5(3): 315-326.
31. Ehara T, Shigematsu H. Contribution of mast cells to the tubulointerstitial lesions in IgA nephritis. Kidney Int 1998; 54(5): 1675-1683.
32. Konishi Y, Morikawa T, Okada N, et al. Evidence for abundant presence of chymase-positive mast cells in the kidneys of patients with immunoglobulin A nephropathy: effect of combination therapy with prednisolone and angiotensin II receptor blocker valsartan. Hypertens Res 2008; 31(8): 1517-1524.
33. Togawa H, Nakanishi K, Shima Y, et al. Increased chymasepositive mast cells in children with crescentic glomerulonephritis. Pediatr Nephrol 2009; 24(5): 1071-1075.
34. Otsubo S, Nitta K, Uchida K, Yumura W, Nihei H. Mast cells and tubulointerstitial fibrosis in patients with ANCA-associated glomerulonephritis. Clin Exp Nephrol 2003; 7(1): 41-47.
35. Ruger BM, Hasan Q, Greenhill NS, Davis PF, Dunbar PR, Neale TJ. Mast cells and type VIII collagen in human diabetic nephropathy. Diabetologia 1996; 39(10): 1215-1222.
36. Jones SE, Gilbert RE, Kelly DJ. Tranilast reduces mesenteric vascular collagen deposition and chymase-positive mast cells in experimental diabetes. J Diabetes Complications 2004; 18(5): 309-315.
37. Yamada M, Ueda M, Naruko T, et al. Mast cell chymase expression and mast cell phenotypes in human rejected kidneys. Kidney Int 2001; 59(4): 1374-1381.
38. Goto E, Honjo S, Yamashita H, Shomori K, Adachi H, Ito H. Mast cells in human allografted kidney: correlation with interstitial fibrosis. Clin Transplant 2002; 16(8): 7-11.
39. El-Koraie AF, Baddour NM, Adam AG, El Kashef EH, El Nahas AM. Role of stem cell factor and mast cells in the progression of chronic glomerulonephritides. Kidney Int 2001; 60(1): 167-172.
40. Kurusu A, Suzuki Y, Horikoshi S, Shirato I, Tomino Y. Relationship between mast cells in the tubulointerstitium and prognosis of patients with IgA nephropathy. Nephron 2001; 89(4): 391-397.
41. Liu H, Liu F, Peng Y, et al. Role of mast cells, stem cell factor and protease-activated receptor-2 in tubulointerstitial lesions in IgA nephropathy. Inflamm Res 2010; 59(7): 551-559.
42. Kitoh T, Ishikawa H, Ishii T, Nakagawa S. Elevated SCF levels in the serum of patients with chronic renal failure. Br J Haematol Sep 1998; 102(5): 1151-1156.
43. Husain A KA, Sung SS, Urata H, Bumpus FM. Human heart chymase. In the Cardiac Renin-Angiotensin System. Mount Kisco, NY: Futura Medical Publishers; 1994.
44. Husain A. The chymase-angiotensin system in humans. J Hypertens 1993; 11(11): 1155-1159.
45. Mangiapane ML, Rauch AL, MacAndrew JT, et al. Vasoconstrictor action of angiotensin I-convertase and the synthetic substrate (Pro11, D-Ala12)-angiotensin I. Hypertension Jun 1994; 23(6 Pt 2): 857-860.
46. Nishimoto M, Takai S, Sawada Y, et al. Chymase-dependent angiotensin II formation in the saphenous vein versus the internal thoracic artery. J Thorac Cardiovasc Surg 2001; 121(4): 729-734.
47. McDonald JE, Padmanabhan N, Petrie MC, Hillier C, Connell JM, McMurray JJ. Vasoconstrictor effect of the angiotensin-converting enzyme-resistant, chymase-specific substrate [Pro(11)(D)-Ala(12)] angiotensin I in human dorsal hand veins: in vivo demonstration of non-ace production of angiotensin II in humans. Circulation 2001; 104(15): 1805-1808.
48. Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 2006; 69(2): 213-217.
49. Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature 1990; 346(6282): 371-374.
50. Bottinger EP, Bitzer M. TGF-beta signaling in renal disease. J Am Soc Nephrol 2002; 13(10): 2600-2610.
51. Schnaper HW, Hayashida T, Hubchak SC, Poncelet AC. TGF-beta signal transduction and mesangial cell fibrogenesis. Am J Physiol Renal Physiol 2003; 284(2): F243-252.
52. Wolf G, Mueller E, Stahl RA, Ziyadeh FN. Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-beta. J Clin Invest Sep 1993; 92(3): 1366-1372.
53. Wolf G. Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-beta pathway. Kidney Int 2006; 70(11): 1914-1919.
54. Koibuchi Y, Lee WS, Gibbons GH, Pratt RE. Role of transforming growth factor-beta 1 in the cellular growth response to angiotensin II. Hypertension 1993; 21(6 Pt 2): 1046-1050.
55. Taipale J, Lohi J, Saarinen J, Kovanen PT, Keski-Oja J. Human mast cell chymase and leukocyte elastase release latent transforming growth factor-beta 1 from the extracellular matrix of cultured human epithelial and endothelial cells. J Biol Chem 1995; 270(9): 4689-4696.
56. Zhao XY, Zhao LY, Zheng QS, et al. Chymase induces profibrotic response via transforming growth factor-beta 1/Smad activation in rat cardiac fibroblasts. Mol Cell Biochem 2008; 310(1-2): 159-166.
57. Wasse H, Rivera AA, Huang R, et al. Increased Plasma Chymase Concentration and Mast Cell Chymase Expression in Venous Neointimal Lesions of Patients with CKD and ESRD. Seminars in Dialysis 2011; 24(6): 688-693.
58. Scandiuzzi L, Beghdadi W, Daugas E, et al. Mouse mast cell protease-4 deteriorates renal function by contributing to inflammation and fibrosis in immune complex-mediated glomerulonephritis. J Immunol 2010; 185(1): 624-633.
59. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003; 92(8): 827-839.
60. Sharma AK, Mauer SM, Kim Y, Michael AF. Altered expression of matrix metalloproteinase-2, TIMP, and TIMP-2 in obstructive nephropathy. J Lab Clin Med 1995; 125(6): 754-761.
61. Uchio K, Manabe N, Tamura K, et al. Decreased matrix metalloproteinase activity in the kidneys of hereditary nephrotic mice (ICGN strain). Nephron 2000; 86(2): 145-151.
62. Tchougounova E, Lundequist A, Fajardo I, Winberg JO, Abrink M, Pejler G. A key role for mast cell chymase in the activation of promatrix metalloprotease-9 and pro-matrix metalloprotease-2. J Biol Chem 2005; 280(10): 9291-9296.
63. Stewart JA, Jr., Wei CC, Brower GL, et al. Cardiac mast cell-and chymase-mediated matrix metalloproteinase activity and left ventricular remodeling in mitral regurgitation in the dog. J Mol Cell Cardiol 2003; 35(3): 311-319.
64. Cheng S, Pollock AS, Mahimkar R, Olson JL, Lovett DH. Matrix metalloproteinase 2 and basement membrane integrity: a unifying mechanism for progressive renal injury. FASEB J 2006; 20(11): 1898-1900.
65. Sadjadi J, Kramer GL, Yu CH, et al. Angiotensin converting enzyme-independent angiotensin ii production by chymase is up regulated in the ischemic kidney in renovascular hypertension. J Surg Res 2005; 127(2): 65-69.
66. Tokuyama H, Hayashi K, Matsuda H, et al. Differential regulation of elevated renal angiotensin II in chronic renal ischemia. Hypertension 2002; 40(1): 34-40.
67. Leehey DJ, Singh AK, Alavi N, Singh R. Role of angiotensin II in diabetic nephropathy. Kidney Int Suppl 2000; 77: S93-98.
68. Cristovam PC, Arnoni CP, de Andrade MC, et al. ACE-dependent and chymase-dependent angiotensin II generation in normal and glucose-stimulated human mesangial cells. Exp Biol Med (Maywood) 2008; 233(8): 1035-1043.
69. Durvasula RV, Shankland SJ. Activation of a local renin angiotensin system in podocytes by glucose. Am J Physiol Renal Physiol 2008; 294(4): F830-839.
70. Prasad P, Tiwari AK, Kumar KM, et al. Chronic renal insufficiency among Asian Indians with type 2 diabetes: I. Role of RAAS gene polymorphisms. BMC Med Genet 2006; 7: 42.
71. Boffa JJ, Lu Y, Placier S, Stefanski A, Dussaule JC, Chatziantoniou C. Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases. J Am Soc Nephrol 2003; 14(5): 1132-1144.
72. Sharma R, Prasad V, McCarthy ET, et al. Chymase increases glomerular albumin permeability via protease-activated receptor-2. Mol Cell Biochem 2007; 297(1-2): 161-169.
73. Sun J, Zhang J, Lindholt JS, et al. Critical role of mast cell chymase in mouse abdominal aortic aneurysm formation. Circulation 2009; 120(11): 973-982.
74. Hochegger K, Siebenhaar F, Vielhauer V, et al. Role of mast cells in experimental anti-glomerular basement membrane glomerulonephritis. Eur J Immunol 2005; 35(10): 3074-3082.
75. Wang Y, Gu Y, Lewis DF, Alexander JS, Granger DN. Elevated plasma chymotrypsin-like protease (chymase) activity in women with preeclampsia. Hypertens Pregnancy 2010; 29(3): 253-261.
76. Raymond WW, Su S, Makarova A, et al. Alpha 2-macroglobulin capture allows detection of mast cell chymase in serum and creates a reservoir of angiotensin II-generating activity. J Immunol 2009; 182(9): 5770-5777.
77. Hermans WR, Rensing BJ, Foley DP, et al. Therapeutic dissection after successful coronary balloon angioplasty: no influence on restenosis or on clinical outcome in 693 patients. The MERCATOR Study Group (Multicenter European Research Trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis). J Am Coll Cardiol 1992; 20(4): 767-780.
78. Faxon DP. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group. J Am Coll Cardiol 1995; 25(2): 362-369.
79. Peters S, Trummel M, Meyners W, Koehler B, Westermann K. Valsartan versus ACE inhibition after bare metal stent implantation-results of the VALVACE trial. International Journal of Cardiology 2005; 98(2): 331-335.
80. Peters S, Gotting B, Trummel M, Rust H, Brattstrom A. Valsartan for prevention of restenosis after stenting of type B2/C lesions: the VAL-PREST trial. J Invasive Cardiol 2001; 13(2): 93-97.
81. Turan T, van Harten JG, de Water R, Tuncay OL, Kok DJ. Is enalapril adequate for the prevention of renal tissue damage caused by unilateral ureteral obstruction and/or hyperoxaluria? Urol Res 2003; 31(3): 212-217.
82. Fan YY, Nishiyama A, Fujisawa Y, et al. Contribution of chymasedependent angiotensin II formation to the progression of tubulointerstitial fibrosis in obstructed kidneys in hamsters. J Pharmacol Sci 2009; 111(1): 82-90.
83. Maeda Y, Inoguchi T, Takei R, et al. Inhibition of chymase protects against diabetes-induced oxidative stress and renal dysfunction in hamsters. Am J Physiol Renal Physiol 2010; 299(6): F1328-1338.
84. Walker ME, Hatfield JK, Brown MA. New insights into the role of mast cells in autoimmunity: Evidence for a common mechanism of action? Biochimica et biophysica acta 2012; 1822(1): 57-65.
85. Schanstra JP, Neau E, Drogoz P, et al. In vivo bradykinin B2 receptor activation reduces renal fibrosis. The Journal of clinical investigation 2002; 110(3): 371-379.
86. Naito T, Ma LJ, Yang H, et al. Angiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker effects on kidney fibrosis. American journal of physiology Renal physiology 2010; 298(3): F683-691.